347 KEYNOTE-365 cohort C: pembrolizumab + enzalutamide in patients with abiraterone acetate–pretreated metastatic castration-resistant prostate cancer (mCRPC)—data after minimum of 22 months of follow-up

oleh: Urban Emmenegger, Howard Gurney, Emanuela Romano, Neal Shore, Margitta Retz, Christian Poehlein, Charles Schloss, Leonard Appleman, Gwenaelle Gravis, Loïc Mourey, Josep Piulats, Evan Yu, Johann De Bono, William Berry, Peter Fong, Cristiano Ferrario, Tilman Todenhoefer, Henry Conter, Brigitte Laguerre, Xin Tong Li

Format: Article
Diterbitkan: BMJ Publishing Group 2021-11-01

Deskripsi

No description available for this item.